

## Review

# Use of live bacterial vaccine vectors for antigen delivery: potential and limitations

Eva Medina, Carlos Alberto Guzmán \*

*Department of Microbial Pathogenesis and Vaccine Research, Division of Microbiology, GBF-German Research Center for Biotechnology, Mascheroder Weg 1, D-38124 Braunschweig, Germany*

Received 12 May 2000; accepted 11 September 2000

---

## Abstract

Most infectious agents are restricted to the mucosal membranes or their transit through the mucosa constitutes a critical step in the infection process. Therefore, the elicitation of an efficient immune response, not only at systemic, but also at mucosal level, after vaccination is highly desirable, representing a significant advantage in order to prevent infection. This goal can be only achieved, when the vaccine formulation is administered by the mucosal route. However, soluble antigens given by this route are usually poorly immunogenic. Among the available approaches to stimulate efficient mucosal responses, the use of bacterial carriers to deliver vaccine antigens, probably, constitutes one of the most successful strategies. The potential and limitations of the most extensively studied bacterial carrier systems will be discussed. © 2001 Elsevier Science Ltd. All rights reserved.

**Keywords:** Carriers; Mucosal immunity; Vaccines

---

## 1. Introduction

Vaccination constitutes the most cost-effective tool for the prophylaxis of infectious diseases. Most pathogenic microorganisms are either restricted to the mucosal membranes or need to transit them during the early steps of the infection [1]. Therefore, the elicitation of an efficient immune response at mucosal level after immunization is highly desirable [2]. This may result in a more efficient protection against infection, also facilitating the eradication of diseases for which humans are the only reservoirs. Due to the apparent compartmentalization of the systemic and mucosal immune system, parenterally administered vaccines are less effective in protecting against mucosal pathogens [3,4]. Thus, administration of immunogens through the mucosal route is required to achieve full protection [3,4]. In addition, the use of the

mucosal route is associated by itself with a considerable number of additional advantages (Table 1).

Different strategies can be used to deliver vaccine antigens by the mucosal route. Among them, the use of bacterial carriers, probably, constitutes the most studied strategy (Table 2). Delivery of vaccine antigens by live bacterial carriers has resulted in the elicitation of effective humoral and cellular responses, at the level of both systemic and mucosal compartments [5].

## 2. Vaccine delivery systems based on live bacterial vectors

Live vaccine vectors are delivered at the mucosal surface, place in which the onset of infection takes place and the first defense line is laid. On the basis of a common mucosal system, the generated immune response will not only be present at the specific inductive site in which antigen priming took place, but also at remote mucosal sites [3,4]. In addition to the general advantages mentioned in Table 1, the use of bacterial carriers is associated with other benefits, such as low

---

\* Corresponding author. Tel.: +49-531-6181558; fax: +49-531-6181411.

E-mail address: cag@gbf.de (C.A. Guzmán).

batch preparation costs, facilitated technology transfer following development of the prototype, increased shelf-life and stability in the field respect to other formulations (e.g. subunit vaccines), easy administration and low delivery costs. Taken together, these advantages make this strategy particularly suitable for mass immunization programs. By using a carrier as source for a recombinant antigen, the presence of any additional products from the pathogen, which might be reactogenic, is ruled out (e.g. potential traces of copurified products in acellular vaccines). Thus, the carrier operationally becomes an equivalent of a subunit recombinant vaccine. This may in turn facilitate the critical evaluation of antigen-related side effects during clinical phases, when well-characterized carriers are used.

Both attenuated and commensal microorganisms have been successfully used as carriers for vaccine antigens (Table 3). The use of attenuated pathogens seems particularly attractive, since protection against the pathogen itself and immune responses specific for the heterologous antigen(s) can be simultaneously achieved. The efficacy of an attenuated vaccine carrier relies on a subtle balance between minimal reactogenicity and maximal immunogenicity. The background of the carrier strain used in the formulation, the type of mutation selected to achieve attenuation, and the intrinsic properties of the immunogen seem to be crucial in determining the extent and quality of the immune response elicited [6,7] (Table 4). The bacterial species, which have been considered suitable as antigen delivery systems and exhibit a satisfactory immunogenicity profile will be briefly reviewed.

**Table 1**  
Advantages associated with vaccine administration by the mucosal route

Mucosal administration	Parenteral administration
Low reactogenicity	Generally higher reactogenicity than mucosal
High acceptance/increased compliance	Pain = reduced acceptance/reduced compliance
Inductive sites are targeted	Inductive sites are not targeted
Systemic and mucosal responses are stimulated	Only systemic responses are stimulated
Protection against disease and infection	Mainly protection against disease
No cross contamination/increased safety	Potential risk of cross contamination
Easy administration/simple logistics	Requirement of trained personnel
Low delivery associated costs	Higher delivery costs

**Table 2**  
Strategies used to administer vaccines by the mucosal route

Mucosal antigen delivery systems	
•	live viral or bacterial vaccine carriers
•	mucosal adjuvants
•	viral particles
•	ISCOMs
•	liposomes
•	microparticles
•	transgenic plants

## 2.1. *Listeria monocytogenes*

*L. monocytogenes* is a Gram-positive intracellular pathogen, which has been considered as the prototype for the elicitation of MHC class I-restricted immune responses. This microorganism can stimulate strong cell-mediated responses against its own proteins or co-expressed antigens. The ability of *L. monocytogenes* to breach into the cytoplasm of infected cells allows that the expressed proteins gain access to the endogenous antigen-processing pathway, facilitating epitope presentation in the context of MHC class I molecules [8,9]. This type of immune response is considered to be particularly important for the clearance of intracellular bacterial pathogens, viruses, tumors and parasites [8,10–13].

Different mutations in virulence-associated determinants of *L. monocytogenes* have been exploited to develop attenuated strains amenable for use as live carriers [9]. Attenuated *L. monocytogenes* vaccine carriers have been used to stimulate strong cellular immune responses (mainly CD8 + CTL) against different viruses [9,14–18] and for the immunotherapy of cancer [19–22]. Vaccination with bacteria expressing tumor-associated antigens has been shown to protect animals, not only against lethal challenge with tumor cells, but also to cause regression of preestablished macroscopic tumors in an antigen-specific T cell-dependent manner [19–22].

**Table 3**  
Live bacterial vectors which have been successfully used as antigen delivery systems

Attenuated mucosal pathogens	Commensal strains
<i>L. monocytogenes</i>	<i>S. gordonii</i>
<i>Salmonella</i> spp.	<i>Lactobacillus</i> spp.
<i>V. cholerae</i>	<i>Staphylococcus</i> spp.
<i>Shigella</i> spp.	
<i>M. bovis</i> BCG	
<i>Y. enterocolitica</i>	
<i>B. anthracis</i>	

Table 4

General factors to be considered to optimize the immune responses stimulated by bacterial carriers

Carrier-related factors	Antigen-related factors
Selection of the carrier	Intrinsic properties of the antigen
Specific background strain	Expression system
Attenuating mutation	Antigen-display form
Level of attenuation	Stabilization of the recombinant phenotype
Stabilization of the attenuated phenotype	Co-expression of modulating molecules
Establishment of the optimal dosage	Vaccination schedule

## 2.2. *Salmonella* spp.

*Salmonella* are intracellular pathogens that remain restricted to the endosomal compartment of eukaryotic cells, resisting non specific killing mechanisms [23]. The introduction of defined non-reverting mutations affecting critical virulence factors from *Salmonella* has been used to generate an array of live vaccine carriers. Although many attenuated mutants were constructed and characterized for virulence in the mouse model, only a few of them have been evaluated as vaccine carriers. Mutants deficient in the biosynthesis of aromatic amino acids or purines, production of adenylyl cyclase or cAMP receptor protein, carrying mutations affecting the global regulatory system *phoP/phoQ* or lacking the DNA adenine methylase, have been the most widely characterized [24–30]. These mutants are excellent carriers for vaccine antigens from other bacteria [31,32], viruses [33,34], parasites [35,36], and tumors [37], being able to stimulate strong systemic and local immune responses against the corresponding antigens. Therefore, vaccine prototypes based on attenuated *Salmonella* strains can be employed, when effective humoral responses are required (e.g. to achieve clearance of extracellular pathogens) and also for clinical situations in which Th1 helper and/or cytotoxic effector cells are needed (e.g. viral diseases and tumors).

## 2.3. *Yersinia enterocolitica*

*Y. enterocolitica* is an enteric pathogen able to invade intestinal tissues, resisting host clearance mechanisms. The invasion of intestinal cells by *Y. enterocolitica* is largely dependent on the presence of a virulence plasmid [38], which codes for the synthesis of several virulence determinants. These proteins are synthesized during the invasion phase and are able to stimulate a strong antibody response. Recombinant *Y. enterocolitica* strains have been used as carriers for heterologous antigens, leading to the elicitation of efficient and pro-

teactive immune responses at systemic and mucosal levels [39–41]. The antigen-specific secretory IgA triggered by *Y. enterocolitica* was found, not only in the intestine, but also in the respiratory tract [42].

## 2.4. Commensal microorganisms

*Lactobacillus* belong to the normal flora from the gut and the genitourinary tract, and have been widely used as probiotics in the food industry. In addition to their wide acceptance by the public and their intrinsic safety profile, a large variety of biological and immunomodulatory properties make them attractive candidates as carriers for mucosal vaccination [43]. Different *Lactobacillus*-based vaccine prototypes have been developed and administered by the mucosal route, leading to the elicitation of both mucosal and systemic immune responses against the expressed antigens [44,45]. *Streptococcus gordonii* is also a commensal microorganism, which has been exploited as carrier. Different recombinant antigens from human pathogens have been successfully expressed and delivered using this system [46–49].

Many viral and bacterial pathogens have their port of entry at the level of the genital mucosa. Therefore, the elicitation of an efficient local response at the target site constitutes an important goal for the development of efficient vaccines against sexually transmitted diseases. Both *S. gordonii* and *Lactobacillus* spp. can be employed to develop vaccines against sexually transmitted pathogens. Recombinant strains of *S. gordonii* expressing the V3 domain of the gp120 protein of the HIV-1 virus or the E7 protein of human papillomavirus have been engineered. Antigen-specific local (secretory IgA) and systemic (humoral and cellular) responses were observed in vaccinated monkeys [48,49].

## 2.5. Other bacterial carrier systems

*Mycobacterium bovis* BCG represents the most widely used attenuated bacterial vaccine all over the world. Therefore, its potential use as bacterial carrier for heterologous antigens appears as extremely attractive. The stimulation of protective immune responses by prototypes expressing HIV antigens can be mentioned among the studies showing more promising results [50,51].

The *Bacillus anthracis* toxinogenic Sterne strain is currently used as a live veterinary vaccine against anthrax. Attenuated strains of *B. anthracis* expressing heterologous antigens seem to exhibit a significant potential as carriers for veterinary vaccines [52–54].

As previously mentioned, attenuated vaccine strains developed to protect against intestinal pathogens can also be used as carriers. The expression of protective antigens from other microorganisms would, thereby,

facilitate the development of multicomponent vaccines [55]. As an example, a live candidate against shigellosis was developed using the attenuated cholera vaccine strain *Vibrio cholerae* 103 Hg<sup>R</sup> as a carrier for the *Shigella sonnei* O-antigen [56]. Vaccination with this prototype resulted in the elicitation of high titres of *S. sonnei* O-antigen-specific antibodies in vaccinated animals [57]. Other examples have been provided by candidates based on the attenuated *Shigella flexneri* aroD strain SFL124, which was used to express antigens from *Shigella dysenteriae* I. The administration of the generated prototypes by mucosal route led to the stimulation of protective responses [58–60].

### 3. Use of live bacterial vectors as vehicles for the delivery of DNA vaccines

DNA vaccination is a new approach for the elicitation of efficient responses by employing genes encoding the vaccine antigen, rather than using the proteins themselves [61]. The fact that many attenuated bacterial vectors are specifically targeted to the antigen presenting cells at inductive sites suggested that they could also be used to specifically deliver DNA to them. In this context, the recombinant antigen will not be expressed by the carrier itself, but rather the gene encoding the vaccine antigen will be delivered to host cells. Thus, to the general advantages of the mucosal delivery, the benefits associated with DNA vaccination should be added (e.g. technical easiness, post-translational modifications of the synthesized product, etc.). Microorganisms which have the capacity to access the cytoplasm of infected cells, such as *Shigella* and *Listeria*, have been used to deliver DNA constructs in which the expression of the recombinant antigen was under the control of a eukaryotic promoter [62,63]. The in vitro efficiency of the *Listeria*-based system has been increased by using conditional self-destructing carriers engineered to produce a phage lysin [63]. Attenuated *Salmonella* strains can also be used for the delivery of DNA to eukaryotic cells [64–66]. It was demonstrated that *Salmonella*-based vaccines can be used to prevent both infections and tumors by specifically targeting antigen presenting cells, and that this approach can also be used to correct genetic defects in macrophages [64–66].

### 4. Modulation of the immune responses stimulated by live bacterial carriers

The successful resolution of infections caused by microbial pathogens is determined, to a great extent, by the balance achieved between the different cellular populations which are stimulated. CD4 + Th cells can differentiate into two distinct types of effector cells,

Th1 cells, which regulate cell-mediated immunity, and Th2 cells, which mainly regulate humoral immune responses [67]. It has been demonstrated that the elicitation of Th2-type responses is particularly important to achieve protection against certain parasitic infections [68]. In contrast, Th1-type responses enhance the microbicidal activity of macrophages, facilitating the clearance of intracellular pathogens [8,69]. Therefore, evaluation and selection of the most adequate strategy to stimulate the required quality of immune response is an essential step during the vaccine design phase. The rational exploitation of attenuated bacterial strains as antigen delivery system may require the development of strategies to stimulate appropriate effector populations according to the specific needs [70].

The type of the microorganism which will be selected as a carrier is a critical factor to be considered. In fact, the intracellular compartment where the carrier resides has a decisive impact on the type of T cell sub-population to be stimulated following vaccination. CD8 + T cells are the main cellular population stimulated during infection with *L. monocytogenes* [8]. On the other hand, CD4 + T cells seem to be the main effector population triggered during *Salmonella* infection [71], although a role for CD8 + T cells has also been demonstrated [72,73].

The quality of the evoked immune response not only depends on the general properties of the carrier, but also on the nature of the specific mutation affecting the virulence properties. This feature has been exploited to fine-tune the quality of the immune response elicited by the carrier strain [6,7]. Therefore, the availability of a well-characterized panel of mutants able to promote specific types of immune responses (e.g. different Th patterns) might allow to modulate the obtained responses by selecting the most appropriate mutant according to the specific application. Interestingly, the quality of the immune response generated by the vaccine antigen is not entirely determined by the selected carrier or the nature of the immunogen, but it is also influenced by the particular promoter chosen to drive antigen expression [74]. The Th pattern response stimulated by the carrier was shifted from a mixed Th1/Th2 to a dominant Th1 by just using different promoters to control the expression of the vaccine antigen, leading to an improved efficacy of the prototype [74].

The form of antigen display by the carrier and the compartment where the recombinant antigen is expressed can also influence the quality of the triggered response. Depending on the topology, the antigen can gain access to either the MHC class I or II degradation pathway, which in turn will influence the generation of antigen-specific CD4 + and/or CD8 + T cells. Using appropriated expression systems, the vaccine antigen can be either secreted into the environment, displayed attached to the carrier surface or retained into the

cytoplasm [15,20,36,58,59,75–79]. The secretion apparatus of the hemolysin of *Escherichia coli* has been the most extensively used, leading to an overall increment of the efficacy of the vaccine candidates [59,75–79]. However, secretion has been shown to be dependent on the folding rate of the specific protein [78]. This problem can be solved by the expression of only selected epitopes, which play a critical role in the elicitation of a protective response.

As mentioned above, the global quality of the immune response stimulated against the heterologous antigen is, to a large extent, predetermined by the dominant type of immunity promoted by the carrier itself. However, this can be modified by co-administering or co-expressing specific modulating cytokines, which can modify the polarization pattern of the stimulated T cells [80].

## 5. Problems associated with the use of live bacterial carriers

### 5.1. Reversion to virulence and/or reactogenicity

The carrier strains used as backbone for the generation of vaccine prototypes should exhibit an adequate safety profile. Strains belonging to the same bacterial species and carrying identical attenuating mutations may show different in vivo performances as a result of their strain-specific virulence profile. In addition, when attenuated pathogens are used as carriers, the stability of the attenuated phenotype should be ensured. This can be achieved by selecting specific target genes/loci for which singular inactivation results in attenuation. Subsequently, independent deletions should be introduced in two or more of these genes. This would eliminate or make negligible the risk of reversion to virulence, as a result of recombination events or horizontal gene transfer.

For vaccine prototypes based on attenuated enteropathogenic bacteria, the therapeutic window may be significantly different in endemic versus non endemic areas. Due to pre-existing immunity, the vaccine dose required to trigger efficient responses in non-endemic areas may be ineffectual in countries in which wild type strains are normally circulating. Conversely, the established dosage for endemic areas might be reactogenic in non-endemic areas. A potential solution for this dilemma might be the presentation of the vaccine in different formulations, according to the geographic area.

### 5.2. Stability of the recombinant phenotype

The use of bacterial strains as vaccine carriers for heterologous antigens raises the issue of selecting the

most appropriate expression strategy to optimize the production of the recombinant antigen, thereby, warranting carrier competitiveness, reproducibility and efficacy. The use of plasmids is often associated with instability of the recombinant phenotype. Furthermore, the presence of antibiotic resistance markers in strains which will be delivered under uncontaminated conditions is not desirable. The use of low copy number vectors and/or their modification by inclusion of killing systems, partition functions and non antibiotic selection markers have improved their performance and safety profiles [59,60,79,81]. Stability can also be achieved by integrating the cassettes coding for the heterologous antigens into the chromosome of the carrier strain [59,60]. However, the low expression levels obtained using a monocopy gene dosage, may result to be insufficient to stimulate efficient responses [82]. To circumvent this problem, alternative expression strategies, such as the use of in vivo activated promoters, have been proposed [74,83].

### 5.3. Horizontal gene transfer

The expression of particular vaccine antigens by non pathogenic commensals or environmental microorganisms, may increase their virulence for human or animal populations. In this context, the release of a live vector containing such gene(s) may represent an environmental risk. Therefore, it might be necessary for specific applications, to establish systems to minimize the possibility of horizontal gene transfer from the vaccine strain to members of the mucosal flora or environmental microorganisms. This can be achieved by using different strategies, such as the incorporation of conditional lethal systems [84,85].

### 5.4. Pre-existing immunity

The possibility that prior exposure to the bacterial vector might compromise the efficacy of the initial or additional vaccine constructs, which are based in the same microorganism, has been demonstrated by using *Salmonella* spp. [86]. The immune responses elicited against the heterologous antigen were dramatically impaired in situations of pre-existing immunity against the carrier strain. By using different carrier species or bacterial serotypes for the preparation of different formulations, this problem can be circumvented. Alternatively, the establishment of an optimal window for the re-administration of the carrier may contribute to eliminate this bottleneck.

### 5.5. Host genetic factors

Host genetic factors may modulate the immune response stimulated by the live bacterial carrier itself or

the expressed vaccine antigens. This aspect should also be taken into consideration, when live vaccine candidates are developed and/or tested. In this regard, it has been shown that the diversity of the mouse H-2 haplotype can determine the development of an efficient CD4+ Th1 response against a recombinant antigen expressed by *S. typhimurium* [87]. In mice, early bacterial replication following infection with *S. typhimurium* is controlled by the gene *Nramp1* (natural-resistance-associated macrophage protein), which might also influence responses to recombinant antigens expressed by this bacterium. Experiments using mice congenic for *Nramp1* evidenced that in those carrying the resistance allele a dominant Th1 response was stimulated, whereas congenic mice carrying the susceptibility allele of *Nramp1* developed a Th2 predominant response [88].

## 6. Conclusions

The use of live bacterial carriers constitutes a powerful tool to achieve an efficient delivery of either vaccine antigens or DNA vaccine constructs. Almost unlimited possibilities are offered for the exploitation of this system in the context of clinical applications, such as immunotherapy and immunoprophylaxis of infectious diseases, cancer or chronic processes. To the multiple advantages associated with the use of the mucosal route, the amplification effect derived from persistent antigen production, increased stability and low production costs should be added. In the last few years, many defined attenuated mutants and expression systems have been generated and tested. These studies performed both in animals and humans gave us a significant knowledge in terms of the immune responses stimulated by bacterial carrier-based vaccines and their overall efficacy to prevent disease. This constitutes a solid platform for the development of new prototypes based in this technology in the years to come.

## References

- [1] Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. *Microbiol Rev* 1983;47(4):510–50.
- [2] Staats HF, Jackson RJ, Marinaro M, Takahashi I, Kiyono H, McGhee JR. Mucosal immunity to infection with implications for vaccine development. *Curr Opin Immunol* 1994;6(4):572–83.
- [3] McGhee JR, Mestecky J, Dertzbaugh MT, Elbridge JH, Hirashima M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. *Vaccine* 1992;10(2):75–88.
- [4] Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Mucosal immunity: implication for vaccine development. *Immunobiology* 1992;184:157–79.
- [5] Medina E, Guzmán CA. Modulation of immune responses following antigen administration by mucosal route. *FEMS Immunol Med Microbiol* 2000;27:305–11.
- [6] VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H, McGhee JR. Regulation of host immune responses by modification of *Salmonella* virulence genes. *Nat Med* 1998;4(11):1247–52.
- [7] Medina E, Paglia P, Nikolaus T, Muller A, Hensel M, Guzman CA. Pathogenicity island 2 mutants of *Salmonella typhimurium* are efficient carriers for heterologous antigens and enable modulation of immune responses. *Infect Immun* 1999;67(3):1093–9.
- [8] Kaufmann SH. Immunity to intracellular bacteria. *Annu Rev Immunol* 1993;11:129–63.
- [9] Guzmán CA, Weiss S, Chakraborty T. *Listeria monocytogenes* a promising vaccine carrier to evoke cellular immune responses. In: Wells J, Pozzi G, editors. *Gram-positive Bacteria as Vaccine Vehicles for Mucosal Immunization*, Biotechnology Intelligence Unit series. Georgetown, TX, USA: R.G. Landes Biomedical Publishers, 1997:145–73.
- [10] Yap KL, Ada GL, McKenzie IF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. *Nature* 1978;273(5659):238–9.
- [11] Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. *J Immunol* 1994;152(2):549–56.
- [12] Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. *Adv Cancer Res* 1992;58:143–75.
- [13] Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. *Proc Natl Acad Sci USA* 1993;90(3):948–52.
- [14] Frankel FR, Hegde S, Lieberman J, Paterson Y. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using *Listeria monocytogenes* as live vaccine vector. *J Immunol* 1995;155(10):4775–82.
- [15] Guzmán CA, Severino D, Medina E, Fenoglio D, Gerstel B, Merlo A, Merlo A, Li Pira G, Buffa F, Chakraborty T, Manca F. Attenuated *Listeria monocytogenes* carrier strains can deliver an HIV-1 gp 120 T helper epitope to MHC class II-restricted human CD4+ T cells. *Eur J Immunol* 1998;28(6):1807–14.
- [16] Shen H, Sliska MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Recombinant *Listeria monocytogenes* as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. *Proc Natl Acad Sci USA* 1995;92(9):3987–91.
- [17] Goossens PL, Milon G, Cossart P, Saron MF. Attenuated *Listeria monocytogenes* as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. *Int Immunol* 1995;7(5):797–805.
- [18] Ikonomidis G, Portnoy DA, Gerhard W, Paterson Y. Influenza-specific immunity induced by recombinant *Listeria monocytogenes* vaccines. *Vaccine* 1997;15(4):433–40.
- [19] Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant *Listeria monocytogenes* vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. *Nat Med* 1995;1(5):471–7.
- [20] Paglia P, Arioli I, Frahm N, Chakraborty T, Colombo MP, Guzmán CA. The defined attenuated *Listeria monocytogenes* *mpl2* mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. *Eur J Immunol* 1997;27(6):1570–5.
- [21] Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant *Listeria monocytogenes* vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. *J Virol* 1997;71(11):8467–74.
- [22] Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant *Listeria monocytogenes* vaccine. *Cancer Res* 1999;59(20):5264–9.

[23] Carroll ME, Jackett PS, Aber VR, Lowrie DB. Phagolysosome formation, cyclic adenosine 3':5'-monophosphate and the fate of *Salmonella typhimurium* within mouse peritoneal macrophages. *J Gen Microbiol* 1979;110(2):421–9.

[24] Hoiseth SK, Stocker BAD. Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* 1981;291(5812):238–9.

[25] O'Callaghan D, Maskell D, Liew FY, Easmon CSF, Dougan G. Characterization of aromatic- and purine-dependent *Salmonella typhimurium*: attenuation, persistence, and ability to induce protective immunity in BALB/c mice. *Infect Immun* 1988;56(2):419–23.

[26] Curtiss R, III, Kelly SM. *Salmonella typhimurium* deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. *Infect Immun* 1987;55(12):3035–43.

[27] Galán JE, Curtiss R, III. Virulence and vaccine potential of *phoP* mutants of *Salmonella typhimurium*. *Microb Pathog* 1989;6(6):433–43.

[28] Guo L, Lim KB, Gunn JS, Bainbridge B, Darveau RP, Hackett M, Miller SI. Regulation of lipid A modifications by *Salmonella typhimurium* virulence genes *phoP-phoQ*. *Science* 1997;276(5310):250–3.

[29] Garcia-Del Portillo F, Pucciarelli MG, Casadesus J. DNA adenine methylase mutants of *Salmonella typhimurium* show defects in protein secretion, cell invasion, and M cell cytotoxicity. *Proc Natl Acad Sci USA* 1999;96:11578–83.

[30] Heithoff DM, Sinsheimer RL, Low DA, Mahan MJ. An essential role for DNA adenine methylation in bacterial virulence. *Science* 1999;284:967–70.

[31] Verma NK, Ziegler HK, Wilson M, Khan M, Safley S, Stocker BA, Schoolnik GK. Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin of *Listeria monocytogenes* by attenuated *Salmonella*. *Vaccine* 1995;13(2):142–50.

[32] Dunne M, al-Ramadi BK, Barthold SW, Flavell RA, Fikrig E. Oral vaccination with an attenuated *Salmonella typhimurium* strain expressing *Borrelia burgdorferi* OspA prevents murine Lyme borreliosis. *Infect Immun* 1995;63(4):1611–4.

[33] Nardelli-Haefliger D, Roden RB, Benyacoub J, Sahli R, Krahenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated *Salmonella typhimurium* elicit mucosal and systemic neutralizing antibodies in mice. *Infect Immun* 1997;65(8):3328–36.

[34] Karem KL, Bowen J, Kuklin N, Rouse BT. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant *Salmonella typhimurium* vaccine strains expressing HSV antigens. *J Gen Virol* 1997;78(Pt2):427–34.

[35] Chacon MR, Londono P, Dougan G, Selkirk ME. Heterologous expression of the cuticular-glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of *Salmonella typhimurium* abrogates H-2 restriction of specific antibody responses. *Parasite Immunol* 1996;18(6):307–16.

[36] Schorr J, Knapp B, Hundt E, Küpper HA, Amann E. Surface expression of malarial antigens in *Salmonella typhimurium*: induction of serum antibody response upon oral vaccination of mice. *Vaccine* 1991;9(9):675–81.

[37] Medina E, Guzmán CA, Staendner LH, Colombo MP, Paglia P. *Salmonella* vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. *Eur J Immunol* 1999;29(2):693–9.

[38] Paerregaard A, Espersen F, Jensen OM, Skurnik M. Interactions between *Yersinia enterocolitica* and rabbit ileal mucus: growth, adhesion, penetration, and subsequent changes in surface hydrophobicity and ability to adhere to ileal brush border membrane vesicles. *Infect Immun* 1991;59(1):253–60.

[39] Sory MP, Hermand P, Vaerman JP, Cornelis GR. Oral immunization of mice with a live recombinant *Yersinia enterocolitica* O:9 strain that produces the cholera toxin B subunit. *Infect Immun* 1990;58(8):2420–8.

[40] O'Gaora P, Roberts M, Bowe F, Hormaeche C, Demarco de Hormaeche R, Cafferkey M, Tite J, Dougan G. *Yersinia enterocolitica* aroA mutants as carriers of the B subunit of the *Escherichia coli* heat-labile enterotoxin to the murine immune system. *Microb Pathog* 1990;9(2):105–16.

[41] Sory MP, Kaniga K, Goldenberg S, Cornelis GR. Expression of the eukaryotic *Trypanosoma cruzi* CRA gene in *Yersinia enterocolitica* and induction of an immune response against CRA in mice. *Infect Immun* 1992;60(9):3830–6.

[42] Van Damme M, Sory MP, Biot T, Vaerman JP, Cornelis GR. Oral immunization against cholera toxin with a live *Yersinia enterocolitica* carrier in mice. *Gastroenterology* 1992;103(2):520–31.

[43] Pouwels PH, Leer RJ, Shaw M, Heijne den Bak-Glashouwer MJ, Tielen FD, Smit E, Martinez B, Jore J, Conway PL. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. *Int J Food Microbiol* 1998;41(2):155–67.

[44] Zegers ND, Kluter E, Van Der Stap H, Van Dura E, Van Dalen P, Shaw M, Baillie L. Expression of the protective antigen of *Bacillus anthracis* by *Lactobacillus casei*: towards the development of an oral vaccine against anthrax. *J Appl Microbiol* 1999;87(2):309–14.

[45] Gerritsse K, Posno M, Schellekens MM, Boersma WJ, Claassen E. Oral administration of TNP-Lactobacillus conjugates in mice: a model for evaluation of mucosal and systemic immune responses and memory formation elicited by transformed lactobacilli. *Res Microbiol* 1990;141(7-8):955–62.

[46] Oggioni MR, Manganelli R, Contorni M, Tommasino M, Pozzi G. Immunization of mice by oral colonization with live recombinant commensal streptococci. *Vaccine* 1995;13(8):775–9.

[47] Medaglini D, Pozzi G, King TP, Fischetti VA. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium *Streptococcus gordonii* after oral colonization. *Proc Natl Acad Sci USA* 1995;92(15):6868–72.

[48] Di Fabio S, Medaglini D, Rush CM, Corrias F, Panzini GL, Pace M, Verani P, Pozzi G, Titti F. Vaginal immunization of cynomolgus monkeys with *Streptococcus gordonii* expressing HIV-1 and HPV 16 antigens. *Vaccine* 1998;16(5):485–92.

[49] Oggioni MR, Medaglini D, Romano L, Peruzzi F, Maggi T, Lozzi L, Bracci L, Zazzi M, Manca F, Valensin PE, Pozzi G. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of *Streptococcus gordonii*. *AIDS Res Hum Retroviruses* 1999;15(5):451–9.

[50] Cirillo JD, Stover CK, Bloom BR, Jacobs WR, Jr, Barletta RG. Bacterial vaccine vectors and bacillus Calmette-Guerin. *Clin Infect Dis* 1995;20(4):1001–9.

[51] Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshizaki H, Kitamura K, Sugiura W, Watanabe K, Fukushima Y, Haga S, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant *Mycobacterium bovis* bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. *Proc Natl Acad Sci USA* 1995;92(23):10693–7.

[52] Sirard JC, Weber M, Duflot E, Popoff MR, Mock M. A recombinant *Bacillus anthracis* strain producing the *Clostridium perfringens* Ib component induces protection against iota toxin. *Infect Immun* 1997;65(6):2029–33.

[53] Sirard JC, Fayolle C, de Chastellier C, Mock M, Leclerc C, Berche P. Intracytoplasmic delivery of listeriolysin O by a vaccinal strain of *Bacillus anthracis* induces CD8-mediated protection against *Listeria monocytogenes*. *J Immunol* 1997;159(9):4435–43.

[54] Brossier F, Mock M, Sirard J. Antigen delivery by attenuated *Bacillus anthracis*: new prospects in veterinary vaccines. *J Appl Microbiol* 1999;87(2):298–302.

[55] Viret JF, Favre D. Bivalent vaccines against bacterial enteropathogens: construction of live attenuated vaccine strains with two O-serotype specificities. *Biologicals* 1994;22(4):361–72.

[56] Viret JF, Cryz SJ, Jr, Favre D. Expression of *Shigella sonnei* lipopolysaccharide in *Vibrio cholerae*. *Mol Microbiol* 1996;19(5):949–63.

[57] Favre D, Cryz SJ, Jr, Viret JF. Development of *Shigella sonnei* live oral vaccines based on defined *rfb* Inaba deletion mutants of *Vibrio cholerae* expressing the *Shigella serotype D* O polysaccharide. *Infect Immun* 1996;64(2):576–84.

[58] Ryd M, Verma N, Lindberg AA. Induction of a humoral immune response to a Shiga toxin B subunit epitope expressed as a chimeric lamB protein in a *Shigella flexneri* live vaccine strain. *Microb Pathog* 1992;12(6):399–407.

[59] Tzschaschel BD, Klee SR, de Lorenzo V, Timmis KN, Guzmán CA. Towards a vaccine candidate against *Shigella dysenteriae* 1: expression of the Shiga toxin B-subunit in an attenuated *Shigella flexneri aroD* carrier strain. *Microb Pathog* 1996;21(4):277–88.

[60] Klee SR, Tzschaschel BD, Fält I, Kärnell A, Lindberg AA, Timmis KN, Guzmán CA. Construction and characterization of live attenuated vaccine candidates against *Shigella dysenteriae* type 1. *Infect Immun* 1997;65:2112–8.

[61] Lai WC, Bennett M. DNA vaccines. *Crit Rev Immunol* 1998;18:449–84.

[62] Sizemore DR, Branstrom AA, Sadoff JC. Attenuated *Shigella* as a DNA delivery vehicle for DNA-mediated immunization. *Science* 1995;270:299–302.

[63] Dietrich G, Bubert A, Gentschev I, Sokolovic Z, Simm A, Catic A, Kaufmann SH, Hess J, Szalay AA, Goebel W. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide *Listeria monocytogenes*. *Nat Biotechnol* 1998;16(2):181–5.

[64] Darji A, Guzmán CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, Weiss S. Oral somatic transgene vaccination using attenuated *Salmonella typhimurium*. *Cell* 1997;91(6):765–75.

[65] Paglia P, Medina E, Arioli I, Guzmán CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with *Salmonella typhimurium*, results in protective immunity against a murine fibrosarcoma. *Blood* 1998;92(9):3172–6.

[66] Montosi G, Paglia P, Garuti C, Guzman CA, Bastin JM, Colombo MP, Pietrangelo A. Wild type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. *Blood* 2000;96(3):1125–9.

[67] Coffman RL, Mosmann TR. CD4+ T-cell subsets: regulation of differentiation and function. *Res Immunol* 1991;142(1):7–9.

[68] Else KJ, Finkelman FD. Intestinal nematode parasites, cytokines and effector mechanisms. *Int J Parasitol* 1998;28(8):1145–58.

[69] Trinchieri G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). *Curr Opin Immunol* 1997;9(1):17–23.

[70] Golding B, Scott DE. Vaccine strategies: targeting helper T cell responses. *Ann NY Acad Sci* 1995;754:126–37.

[71] Nauciell C. Role of CD4+ T cells and T-independent mechanisms in acquired resistance to *Salmonella typhimurium* infection. *J Immunol* 1990;145(4):1265–9.

[72] Pope M, Kotlarski I, Doherty K. Induction of Lyt-2+ cytotoxic T lymphocytes following primary and secondary *Salmonella* infection. *Immunology* 1994;81(2):177–82.

[73] Flynn JL, Weiss WR, Norris KA, Seifert HS, Kumar S, So M. Generation of a cytotoxic T-lymphocyte response using a *Salmonella* antigen-delivery system. *Mol Microbiol* 1990;4(12):2111–8.

[74] Medina E, Paglia P, Rohde M, Colombo MP, Guzmán CA. Modulation of host immune responses stimulated by *Salmonella* vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. *Eur J Immunol* 2000;30:768–77.

[75] Su GF, Brahmbhatt HN, de Lorenzo V, Wehland J, Timmis KN. Extracellular export of Shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in *Salmonella typhimurium* aroA-mutant and stimulation of B-subunit specific antibody responses in mice. *Microb Pathog* 1992;13(6):465–76.

[76] Gentschev I, Mollenkopf H, Sokolovic Z, Hess J, Kaufmann SH, Goebel W. Development of antigen-delivery systems, based on the *Escherichia coli* hemolysin secretion pathway. *Gene* 1996;179(1):133–40.

[77] Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W, Kaufmann SH. Superior efficacy of secreted over somatic antigen display in recombinant *Salmonella* vaccine induced protection against listeriosis. *Proc Natl Acad Sci USA* 1996;93(4):1458–63.

[78] Gentschev I, Dietrich G, Mollenkopf HJ, Sokolovic Z, Hess J, Kaufmann SH, Goebel W. The *Escherichia coli* hemolysin secretion apparatus—a versatile antigen delivery system in attenuated *Salmonella*. *Behring Inst Mitt* 1997;98:103–13.

[79] Tzschaschel BD, Guzmán CA, Timmis KN, de Lorenzo V. An *Escherichia coli* hemolysin transport system-based vector for the export of polypeptides: export of shiga-like toxin II B subunit by *Salmonella typhimurium aroA*. *Nature/Biotechnology* 1996;14:765–9.

[80] Denich K, Borlin P, O'Hanley PD, Howard M, Heath AW. Expression of the murine interleukin-4 gene in an attenuated *aroA* strain of *Salmonella typhimurium*: persistence and immune response in BALB/c mice and susceptibility to macrophage killing. *Infect Immun* 1993;61(11):4818–27.

[81] Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, Sztein MB, Levine MM. Optimization of plasmid maintenance in the attenuated live vector vaccine strain *Salmonella typhi* CVD908-htrA. *Infect Immun* 1999;67(12):6424–33.

[82] Cardenas L, Clements JD. Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. *Vaccine* 1993;11(2):126–35.

[83] Chatfield S, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D, Slater D, Fairweather NF. Use of the *nirB* promoter to direct the stable expression of heterologous antigens in *Salmonella* oral vaccine strains: development of a single-dose oral tetanus vaccine. *Biotechnology* 1992;10(8):888–92.

[84] Munthali MT, Timmis KN, Diaz E. Restricting the dispersal of recombinant DNA: design of a contained biological catalyst. *Biotechnology* 1996;14(2):189–91.

[85] Diaz E, Munthali M, de Lorenzo V, Timmis KN. Universal barrier to lateral spread of specific genes among microorganisms. *Mol Microbiol* 1994;13(5):855–61.

[86] Attridge SR, Davies R, LaBrooy JT. Oral delivery of foreign antigens by attenuated *Salmonella*: consequences of prior exposure to the vector strain. *Vaccine* 1997;15(2):155–62.

[87] Lo-Man R, Martineau P, Deriaud E, Newton SM, Jehanno M, Clement JM, Fayolle C, Hofnung M, Leclerc CD. Control by H-2 genes of the Th1 response induced against a foreign antigen expressed by attenuated *Salmonella typhimurium*. *Infect Immun* 1996;64(11):4424–32.

[88] Soo SS, Villarreal-Ramos B, Anjam Khan CM, Hormaeche CE, Blackwell JM. Genetic control of immune response to recombinant antigens carried by an attenuated *Salmonella typhimurium* vaccine strain: *Nrampl* influences T-helper subset responses and protection against leishmanial challenge. *Infect Immun* 1998;66(5):1910–7.